Table 2.
Clinical characteristics according to treatment modalitya
| Variable | Immunotherapy | No imunotherapy | P |
|---|---|---|---|
| Age (years) |
33.6 ± 18.32 |
40.06 ± 10.31 |
0.481 |
| Male/Female {%} |
4/1 {80/20} |
15/17 {47/53} |
<0.0001 |
| Serum Creatinine (mg/dL) |
1.52 ± 0.55 |
1.20 ± 0.69 |
0.347 |
| CKD EPI eGFR (ml/min/1.73 m2) |
70.06 ± 37.03 |
80.62 ± 29.90 |
0.505 |
| 24 hrs Urinary Protein (mg/day) |
4077.18 ± 3098.19 |
1000.63 ± 899.85 |
<0.0001 |
| Mean Blood Pressure, systolic (mm/Hg) |
128 ± 13 |
125 ± 14.14 |
0.693 |
| Mean Blood Pressure, diastolic (mmHg) |
76 ± 8.3 |
78 ± 8.95 |
0.664 |
| Mesagial hypercellularity (%) |
100 |
59.4 |
<0.0001 |
| Segmental glomerularsclerosis (%) |
100 |
90.7 |
<0.0001 |
| Endocapillary hypercellularity (%) |
80 |
31.3 |
<0.0001 |
| Tubular atrophy/interstitial fibrosis 1 (%) |
0 |
37.5 |
<0.0001 |
| Tubular atrophy/interstitial fibrosis 2 (%) |
60 |
15.7 |
<0.0001 |
| Baseline KIM-1/Cr (ng/mg) |
0.51 [0.31-1.23] |
1.12 [0.62-2.02] |
0.155 |
| Follow-up KIM-1/Cr (ng/mg) |
0.52 [0.01-0.64] |
0.26 [0.13-0.73] |
0.625 |
| Δ KIM-1/Cr (ng/mg) |
0.49 [0.34-0.71] |
0.81 [0.17-1.23] |
0.230 |
| Baseline eGFR (ml/min/1.73 m2) |
70.65 ± 37.03 |
80.62 ± 29.9 |
0.505 |
| Follow-up eGFR (ml/min/1.73 m2) |
72.82 ± 48.44* |
82.26 ± 30.03** |
0.552 |
| Baseline proteinuria (mg/d) |
4855.1 [1569.7-5560.5] |
720 [401-1189.7] |
|
| Follow-up proteinuria (mg/d) |
1323.9 [374.6-1480] |
545.6 [250.5-824] |
|
| P | 0.273 | 0.077 |
aData are expressed as median ± SD or median with interquartile range.
Compared with baseline eGFR: *P = 0.904; **P = 0.572.